Congratulations to Dr. Bob Gray of @HarvardChanSPH @DanaFarber on his retirement as @eaonc Group Statistician! 🎉 We’re grateful for his many contributions to the #CancerResearch community. Wishing him all the best in this next chapter!

The usual treatment for #OlderAdults with early-stage #melanoma includes two surgeries. The EA6244 study asks: could one surgery + close monitoring be just as effective for some people? More info: bit.ly/ea6244-study cc: @YanaNajjarMD @JaniceM10

ECOG-ACRIN launches EA1242/RxFINE-Low: Led by @nancychan29 of @nyulangone, it is the first phase 3 trial asking whether chemotherapy provides additional benefit for high anatomic-risk but low genomic-risk early-stage #BreastCancer patients. Learn more: bit.ly/EA1242

The #ComboMATCH Study, led by researchers from @StanfordCancer, @MDAndersonNews, & @theNCI, is testing new combinations of anti-cancer drugs, based on characteristics found in patients’ tumors or blood. Learn more: bit.ly/ComboMATCH #PrecisionMedicine

Genomic testing changed early-stage #BreastCancer treatment, but why do some cancers still recur? This #BreastCancerAwarenessMonth, learn about EA1241, a study building on TAILORx and RxPONDER to help explain recurrence. #BCSM cc: @carisls, @SWOG bit.ly/EA1241

#Madrid #ESMO26 Presenting Live | Host #InheritedGeneticVariation & the risk of #Hepatitis following #ImmuneCheckpoint #Immunotherapy (ICI) of #Melanoma | Proud of this original collaborative effort & this team at @MoffittNews @eaonc & @theNCI

Kudos @b_szabados @crisuarez08 on awesome rare GU cancers session @myESMO #ESMO26 #ESMOAmbassadors @DrTiborSzarvas @emanuele_crupi @mdesantis234 need subtype-specific trials in bladder Ca & RCC @BladConnect @BladdCancerUS @IBCG_BladderCA @GSRGTPath @arkhaki @eaonc @PavlosMsaouel

Our own @FedGhali, MD (5th from left) was selected as one of just nine early-career investigators nationwide to present research at the 26th Annual @eaonc Young Investigator Symposium. Dr. Ghali shared, “Re-Estimating Treatment Effects Under Contemporary Standard of Care.”

not trying to get more credit. I am honored by having been both. nominated and selected for this award by @eaonc. Just going to note one of my key statements: A full professor who is EVER first author or presenter of new data on the podium missed out on a mentoring opportunity.

Could some patients with early-stage #HER2positive #BreastCancer need less chemotherapy? New findings from our CompassHER2-pCR trial are helping researchers explore who may benefit from a less intensive approach. Learn more from @BCRFcure: bit.ly/4AfHYP1

#ClinicalTrial EA1242/RxFINE-Low, led by @nancychan29 of @Perlmutter_CC, is testing whether #HormoneTherapy plus ribociclib is as effective as chemotherapy followed by hormone therapy plus ribociclib in patients with #BreastCancer. More: bit.ly/ea1242-study

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

#ClinicalTrial EA2234/STOPGAP 2, led by @Senthilsurgonc of @UCIrvineHealth, is testing a new treatment approach for patients with #GastricCancer. Learn more: bit.ly/ea2234-stopgap-ii cc: @NataliyaUboha, @skmaithel

#ClinicalTrial EA7211/STRASS 2, led in the US by @kencardonaMD, is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! bit.ly/EA7211 cc: @EORTC

EA1241, led by @jsparano of @MountSinaiNYC, is a companion study for patients who previously took part in either the TAILORx or RxPONDER #BreastCancer trials. Learn more: bit.ly/EA1241 #bcsm

Do you have newly diagnosed #Glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: bit.ly/gable-trial

It was an honor to present at The Robert L. Comis, MD Translational Science Symposium on the role that inflammation plays in tumorigenesis with the aim to find targets for cancer prevention and interception. Thanks ECOG-ACRIN cancer research group for this incredible opportunity.

Proud of our @SylvesterCancer trainees named Fall 2026 Edith Peterson Mitchell, MD Health Equity Travel Scholars at the @eaonc Meeting in Philadelphia! 🎉 Congrats to our hem-onc fellow @dan_morgen and rad-onc residents @belladreyfuss25 & @xlabissieremd. #HemOnc #RadOnc #HealthEquity #ClinicalTrials

Grateful to @eaonc for the opportunity to present our research and for selecting me among the Young Investigator Award recipients for an oral presentation at the Fall meeting! 🧬🫁 I shared our findings from 14,246 patients with NSCLC, highlighting how the genomic drivers and tumor immune landscape differ across age groups, with important implications for precision oncology. Thankful to my mentor @GlopesMd @SylvesterCancer and all our collaborators for their continued support! @Latinamd @Labcorp @NarjustFlorezMD @DionysiosWatson @DesaiP_Oncdoc

That is a serious group on that stage. Collaborative groups like ECOG-ACRIN are where practice-changing trials actually get done. I'd have loved to be in the room for this one. Kudos for pulling them together. #CancerResearch

Enjoyed the opportunity to present our work developing an AI-powered novel histopathologic biomarker in early-stage NSCLC at the @eaonc Data Science Committee meeting. Thank you for the invitation @ValsamoA! #LCSM #DigitalPathology #LungCancer @CharuAggarwalMD @valarlabs